ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Patience or lose like 4cent David

<< Previous

Bullboard Posts

Next >>

Post by goldtechon Jul 11, 2022 1:16pm

132 Views

Post# 34815568

Patience or lose like 4cent David

Do not expect any huge moves until more clinical data is released, the IND filed and more news related to our science. Those like David King are hit and run losers and will never be part of a huge win if our phase one is a success. So short termers , sell and leave.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec